Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer Appoints Chief Scientific Officer, CV & Metabolic Disease Research

By Drug Discovery Trends Editor | May 29, 2014

Pfizer Inc. announced that Dr. Morris Birnbaum has joined the company as chief scientific officer for Cardiovascular and Metabolic Disease Research. He will report directly to Rod MacKenzie, group senior vice president and head of PharmaTherapeutics Research & Development, and will be based in a key Pfizer R&D hub in Cambridge, Mass. 
 
“As the new leader of our Cardiovascular and Metabolic Disease Research Unit, Birnbaum brings significant scientific expertise that will help us continue the progress of clinical programs in areas of need such as type 2 diabetes, diabetic nephropathy, and hyperlipidemia,” said MacKenzie. “He is among the leading contributors to our contemporary understanding of the regulation of intracellular metabolism, and an excellent addition to our team. His scientific credentials and knowledge will help Pfizer pursue our goals to achieve industry leadership from the strong position that we currently hold, and to deliver unique therapies for patients.” 
 
Birnbaum previously served as the Willard Ware Professor of Diabetes and Metabolic Diseases and Associate Dean for Biomedical Core Resources at the Perelman School of Medicine at the University of Pennsylvania and was also an investigator in the Howard Hughes Medical Institute. Birnbaum has authored more than 200 scientific papers and is the recipient of numerous distinguished awards, including election to the American Association of Clinical Investigation, the American Association of Physicians, and as a Fellow of the American Association for the Advancement of Science. 
 
“I am very impressed by Pfizer’s clear and focused dedication to cardiovascular and metabolic research,” said Birnbaum. “The team has achieved important clinical milestones in the last year alone, and I am excited to bring my expertise and knowledge to the organization so that together we continue to research the next generation of therapies.” 
 
Date: May 29, 2014
Source: Pfizer

Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50